Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Gilead gains late-stage cancer candidate through $465mm purchase of YM BioSciences

Executive Summary

Gilead Sciences Inc. has offered $2.95 per share (an 81% premium), or about $465mm, to purchase cancer and inflammatory disease company YM BioSciences Inc. The Canadian biopharma reported $1mm in revenues for 2012, and had $125mm in cash and cash equivalents as of September 30, 2012.

Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Intra-Biotech Deal
    • Payment Includes Cash for Equity

Related Companies